1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

Sarwish Rafiq PhD; Role: Post Doc Fellow; Current Position: StillWorking in the Lab, MSKCC, New York, NYSwati Pendharkar MD: Role: Research Fellow; Current Position: StillWorking in the lab, MSKCC, New York, NY06/2012-present07/2012-present2. Clinical CareActivityAttending, Outpatient Clinic, Leukemia Service, ½ day per weekAttending, Inpatient Leukemia Service, 8-12 Weeks AnnuallyDates2002-present2002-present3. Administrative dutiesActivityAssociate Director, Cell Mark Laboratory, MSKCCMember, Investigational New Drug (IND) Committee, MSKCCMember, Pharmacy and Therapeutics Committee, MSKCCAssociate Medical Director, Cytotherapy Laboratory, MSKCCMember, Executive Committee, Memorial Hospital Alumni Society,MSKCC (President 2012-13)Member; GMP Working Committee, MSKCCMember, Special Prizes and Awards (SPA) Committee, MSKCCMember, Institutional Bio-safety Committee (IBC) Committee, MSKCCDates2004-present2007-present2008-present2009-present2009-present2011-present2012-present2012-present4. ResearchT cells may be genetically modified to express tumor targeted artificial T cell receptors, termedchimeric antigen receptors (CARs), through retroviral mediated gene transfer. Resulting CARmodified T cells now recognize tumor cells with the capacity to lyse these tumor cells, Using thistechnology our lab has generated a both pre-clinical as well as translational research programwherein we investigate the biology of these CAR modified T cells both in clinically relevantmurine models of disease as well as through currently ongoing clinical trials. To date we haveinvestigated CAR modified T cells targeted to the CD19 antigen expressed on most B cellmalignancies both in preclinical as well as clinical trial studies. Additionally we are investigatingthe potential of CAR modified T cells targeted to ovarian cancer antigens as well as the moreubiquitous WT-1 cancer antigen.7